AstraZeneca Launches Two Nutrition Websites

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 6
Volume 10
Issue 6

WILMINGTON, Del-AstraZeneca Pharmaceuticals has announced the launch of two new websites designed to make nutritional product information and nutritional news more readily available to US health care professionals.

WILMINGTON, Del—AstraZeneca Pharmaceuticals has announced the launch of two new websites designed to make nutritional product information and nutritional news more readily available to US health care professionals.

For the total parenteral nutrition professional, www.TPNpro.com contains articles, news feeds from Reuters News Service, links, tables and a calculator, daily facts from RealAge, and access to continuing education credits.

For information on AstraZeneca’s M.V.I.-12 (multivitamins for infusion) and M.V.I. Pediatric (multivitamins for infusion), including ordering information and patient brochures, professionals can visit www.MVI-us.com. 

Articles in this issue
ACS and NCCN Issue Cancer Pain Management Guidelines for Patients
Xeloda Approved for Metastatic Colorectal Cancer
Walking Improves Fatigue, Sleep in Breast Cancer Patients
Bezwoda 1985 Breast Cancer Transplant Study Fraudulent
Severity of Hot Flashes Worse in Breast Cancer Survivors
Tamoxifen Prevents BRCA2, But Not BRCA1, Breast Cancer
High TIMP-1 Levels May Promote Prostate Cancer Growth
Barriers to Colorectal Cancer Screening Among Minorities
Epoetin Reduces Need for Red Blood Cell Transfusions
French Researchers Discover How HIV Makes First Contact
‘Virtual Supercomputer’ Program for Cancer Drug Discovery
Agent Orange Linked to AML in Offspring
Turkish Towns Provide Genetic Link to Malignant Mesothelioma
President Allows Implementation of Patient Privacy Rule
Gleevec Is Approved for Chronic Myelogenous Leukemia

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Related Content
The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.

FDA ODAC Votes 8-to-1 Against Applicability of Glofitamab DLBCL Data

Russ Conroy
May 20th 2025
Article

The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Data from an ongoing phase 1a/1b trial evaluating ZL-1310 in ES-SCLC will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

ZL-1310 Receives FDA Fast Track Designation for Extensive-Stage SCLC

Roman Fabbricatore
May 20th 2025
Article

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

In the UK, the Medicines and Healthcare products Regulatory Agency approved the belantamab mafodotin combinations in April 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

Belantamab Mafodotin Earns Japanese Approval in R/R Multiple Myeloma

Russ Conroy
May 19th 2025
Article

Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.

56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

Erika King;Elisa Port;Borna Mohabbatizadeh;Christina Weltz;Jacquelyn Dillon;Jacquelyn Amenta;Mayuri Jain
May 19th 2025
Article